Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nanotherapeutics Selects GE Healthcare Life Sciences Technologies

Published: Thursday, February 06, 2014
Last Updated: Thursday, February 06, 2014
Bookmark and Share
FlexFactory™ biomanufacturing platform selected to perform a central role in NANO-ADM Center.

GE Healthcare has announced that biopharmaceutical company Nanotherapeutics, Inc. has selected GE Healthcare Life Sciences' FlexFactory™ biomanufacturing platform to perform a central role in its Advanced Development and Manufacturing (NANO-ADM) Center at Alachua, Florida, USA. Construction of the NANO-ADM Center, which began in October 2013, is expected to be complete in early 2015.

The NANO-ADM Center will fulfill a U.S. Department of Defense contract awarded to Nanotherapeutics in April 2013 to enable faster and more effective development of biomedical countermeasures designed to protect and treat U.S. military personnel against chemical, biological, radiological and nuclear attacks, in addition to protecting against outbreaks of naturally occurring, emerging and genetically engineered infectious diseases.

Following a competitive tender, GE Healthcare has become part of a network of 16 partners, and has been closely involved from the inception of the project, through the contract application process, and on into the construction phase.

Nanotherapeutics’ adoption of GE’s FlexFactory biomanufacturing platform and single-use technologies will help significantly reduce commissioning time and allow rapid reconfiguration of the facility for the manufacture of different products as and when required.

GE’s team of experts in biopharmaceutical manufacturing will provide full training and support in process development to the NANO-ADM Center staff, further accelerating set-up time.

Nigel Darby, Vice President Bioprocess and GE Officer said, “We are delighted to be playing a pivotal role in the establishment and set-up of Nanotherapeutics’ Advanced Development and Manufacturing Center. The wide-ranging and forward-looking criteria of this U.S. Department of Defense contract demands a fast and responsive solution and the flexibility of our established FlexFactory manufacturing platform and the deep sector experience of our team will both be critical components in the success of the program. Being selected by the industry experts at Nanotherapeutics is a clear indication of our reputation as a trusted partner in technologies for biopharmaceutical manufacturing and in process development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BeiGene Selects GE’s FlexFactory™ Biomanufacturing Platform
Facility will manufacture biologics for clinical trials.
Wednesday, December 16, 2015
GE Healthcare and Takeda Join Forces
This alliance is key to enabling the early development of therapeutic drugs through the use of a minimally invasive diagnostic technology.
Thursday, November 13, 2014
UCSF, GE Healthcare Team Up On Pioneering Cord Blood Project
The collaboration aims to overcome the lack of blood-forming stem cells available to patients suffering from life-threatening diseases such as lymphoma, myeloma, leukemia or sickle cell anemia.
Tuesday, December 06, 2011
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!